Structure-guided design of small-molecule therapeutics against RSV disease

Expert Opinion on Drug Discovery

Volumn 11, Issue 6, 2016, Pages 543-556

  Cox, Robert ^a   Plemper, Richard K ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Respiratory syncytial virus; RNA dependent RNA polymerase; small molecule antiviral; viral replication; virus entry

Indexed keywords

EID: 84964521180     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2016.1174212     Document Type: Review

References (125)

1. P.L.C.J.CollinsJr. Respiratory syncytial virus and metapneumoviruses. In: D.M.Knipe, Howley PM, editors. Fields virology. Philadelphia: Lippincott, Williams, & Wilkins; 2007. p. 1601–1645.
2. D.K.Shay, R.C.Holman, G.E.Roosevelt, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183:16–22. doi:10.1086/317655.
3. R.Lozano, M.Naghavi, K.Foreman, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-0.
4. H.Nair, D.J.Nokes, B.D.Gessner, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–1555. doi:10.1016/S0140-6736(10)60206-1.
5. A.R.Falsey Respiratory syncytial virus infection in elderly and high-risk adults. Exp Lung Res. 2005;31(Suppl 1):77.
6. N.Lee, G.C.Lui, K.T.Wong, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57:1069–1077. doi:10.1093/cid/cit471.
7. J.P.DeVincenzo, T.Wilkinson, A.Vaishnaw, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182:1305–1314. doi:10.1164/rccm.201002-0221OC.
8. J.P.DeVincenzo, C.M.El Saleeby, A.J.Bush. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005;191:1861–1868. doi:10.1086/430008.
9. C.M.El Saleeby, A.J.Bush, L.M.Harrison, et al. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011;204:996–1002. doi:10.1093/infdis/jir494.
10. P.J.Mahadevia, F.J.Malinoski. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. Arch Pediatr Adolesc Med. 2007;161:519–520. author reply 520. doi:10.1001/archpedi.161.5.519.
11. L.B.Weiner, A.S.Masaquel, M.J.Polak, et al. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ. 2012;15:997–1018. doi:10.3111/13696998.2012.672942.
12. L.J.Anderson, R.A.Parker, R.L.Strikas. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis. 1990;161:640–646.
13. J.R.Groothuis, K.A.Woodin, R.Katz, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr. 1990;117:792–798.
14. D.W.Johnson. Croup. BMJ Clin Evid. 2009;2009:0321.
15. A.Forster, G.N.Maertens, P.J.Farrell, et al. Dimerization of matrix protein is required for budding of respiratory syncytial virus. J Virol. 2015;89:4624–4635. doi:10.1128/JVI.03500-14.
16. J.P.DeVincenzo, R.J.Whitley, R.L.Mackman, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371:711–722. doi:10.1056/NEJMoa1401184.• study confirmed efficacy in human trial.
17. G.Wang, J.Deval, J.Hong, et al. Discovery of 4ʹ-chloromethyl-2ʹ-deoxy-3ʹ,5ʹ-di-O-isobutyryl-2ʹ-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem. 2015;58:1862–1878. doi:10.1021/jm5017279.
18. J.DeVincenzo, H.Fathi, M.Mcclure, et al. Treatment with oral ALS-008176, a nucleoside analog, rapidly reduces RSV viral load and clinical disease severity in a healthy volunteer challenge study. Open Forum Infect Dis. 2014;1:S66–S69. doi:10.1093/ofid/ofu083.
19. M.A.Krzyzaniak, M.T.Zumstein, J.A.Gerez, et al. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013;9:e1003309. doi:10.1371/journal.ppat.1003309.
20. J.S.McLellan, W.C.Ray, M.E.Peeples. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013;372:83–104. doi:10.1007/978-3-642-38919-1_4.
21. R.A.Karron, D.A.Buonagurio, A.F.Georgiu, et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A. 1997;94:13961–13966.
22. E.E.Walsh, J.Hruska. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol. 1983;47:171–177.
23. M.A.Brindley, P.Plattet, R.K.Plemper. Efficient replication of a paramyxovirus independent of full zippering of the fusion protein six-helix bundle domain. Proc Natl Acad Sci U S A. 2014;111:E3795–3804. doi:10.1073/pnas.1403609111.
24. J.S.McLellan, M.Chen, S.Leung, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340:1113–1117. doi:10.1126/science.1234914.•• first native crystal structure of the RSV F protein in metastable prefusion conformation.
25. V.Razinkov, A.Gazumyan, A.Nikitenko, et al. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol. 2001;8:645–659.
26. K.Andries, M.Moeremans, T.Gevers, et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. 2003;60:209–219.
27. P.R.Wyde, S.N.Chetty, P.Timmerman, et al. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 2003;60:221–231.
28. J.McKimm-Breschkin. VP-14637 ViroPharma. Curr Opin Investig Drugs. 2000;1:425–427.
29. C.Cianci, E.V.Genovesi, L.Lamb, et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother. 2004;48:2448–2454. doi:10.1128/AAC.48.7.2448-2454.2004.
30. J.L.Douglas, M.L.Panis, E.Ho, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol. 2003;77:5054–5064.
31. D.Yan, S.Lee, V.D.Thakkar, et al. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc Natl Acad Sci U S A. 2014;111:E3441–3449. doi:10.1073/pnas.1405198111.•• first demonstration that resistance mutations agaisnt a panel of diverse RSV fusion inhibitors align at the base of the prefusion RSV F head domain and that an recombinant virus strain carrying a signature escape mutation remains fully pathogenic in a small animal model of RSV infection.
32. C.Cianci, K.L.Yu, K.Combrink, et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother. 2004;48:413–422.
33. J.F.Bonfanti, C.Meyer, F.Doublet, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem. 2008;51:875–896. doi:10.1021/jm701284j.
34. D.Roymans, H.L.De Bondt, E.Arnoult, et al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A. 2010;107:308–313. doi:10.1073/pnas.0910108106.
35. M.B.Battles, J.P.Langedijk, P.Furmanova-Hollenstein, et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol. 2015. doi:10.1038/nchembio.1982.• co-crystal structure of RSV fusion inhbitiors with the RSV F protein in prefusion conformation.
36. Centers for Disease C, Prevention. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:433–435.
37. K.L.Stokes, M.H.Chi, K.Sakamoto, et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol. 2011;85:5782–5793. doi:10.1128/JVI.01693-10.
38. D.Yan, M.Weisshaar, K.Lamb, et al. Replication-competent influenza virus and respiratory syncytial virus luciferase reporter strains engineered for co-infections identify antiviral compounds in combination screens. Biochemistry. 2015;54:5589–5604. doi:10.1021/acs.biochem.5b00623.• design of a next-generation RSV reporter strain for HTS drug discovery campaigns engineered to exclude hit candidates sensitive to RSV pan-resistance to entry inhibition.
39. H.Grosfeld, M.G.Hill, P.L.Collins. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J Virol. 1995;69:5677–5686.
40. Q.Yu, R.W.Hardy, G.W.Wertz. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication. J Virol. 1995;69:2412–2419.
41. P.L.Collins, M.G.Hill, E.Camargo, et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5ʹ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A. 1995;92:11563–11567.• demonstration of a critical role of RSV M2-1 in efficient synthesis of viral mRNAs.
42. S.E.Bakker, S.Duquerroy, M.Galloux, et al. The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. J Gen Virol. 2013;94:1734–1738. doi:10.1099/vir.0.053025-0.
43. L.Liljeroos, M.A.Krzyzaniak, A.Helenius, et al. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A. 2013. doi:10.1073/pnas.1309070110.
44. R.G.Tawar, S.Duquerroy, C.Vonrhein, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science. 2009;326:1279–1283. doi:10.1126/science.1177634.• first structural model of an RSV N-RNA complex.
45. K.El Omari, B.Dhaliwal, J.Ren, et al. Structures of respiratory syncytial virus nucleocapsid protein from two crystal forms: details of potential packing interactions in the native helical form. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011;67:1179–1183. doi:10.1107/S1744309111029228.
46. S.K.Khattar, A.S.Yunus, S.K.Samal. Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P and P-L interactions using a minigenome system. J Gen Virol. 2001;82:775–779. doi:10.1099/0022-1317-82-4-775.
47. J.Garcia, B.Garcia-Barreno, A.Vivo, et al. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22 K protein. Virology. 1993;195:243–247. doi:10.1006/viro.1993.1366.
48. A.P.Oliveira, F.M.Simabuco, R.E.Tamura, et al. Human respiratory syncytial virus N, P and M protein interactions in HEK-293T cells. Virus Res. 2013;177:108–112. doi:10.1016/j.virusres.2013.07.010.
49. R.L.Kingston, D.J.Hamel, L.S.Gay, et al. Structural basis for the attachment of a paramyxoviral polymerase to its template. Proc Natl Acad Sci U S A. 2004;101:8301–8306. doi:10.1073/pnas.0402690101.
50. R.Cox, A.Pickar, S.Qiu, et al. Structural studies on the authentic mumps virus nucleocapsid showing uncoiling by the phosphoprotein. Proc Natl Acad Sci U S A. 2014;111:15208–15213. doi:10.1073/pnas.1413268111.
51. F.Yabukarski, P.Lawrence, N.Tarbouriech, et al. Structure of Nipah virus unassembled nucleoprotein in complex with its viral chaperone. Nat Struct Mol Biol. 2014;21. doi:10.1038/nsmb.2868.
52. M.T.Llorente, B.Garcia-Barreno, M.Calero, et al. Structural analysis of the human respiratory syncytial virus phosphoprotein: characterization of an alpha-helical domain involved in oligomerization. J Gen Virol. 2006;87:159–169. doi:10.1099/vir.0.81430-0.
53. D.Karlin, F.Ferron, B.Canard, et al. Structural disorder and modular organization in Paramyxovirinae N and P. J Gen Virol. 2003;84:3239–3252. doi:10.1099/vir.0.19451-0.
54. R.Cox, T.J.Green, S.Purushotham, et al. Structural and functional characterization of the mumps virus phosphoprotein. J Virol. 2013;87:7558–7568. doi:10.1128/JVI.00653-13.
55. J.F.Bruhn, K.C.Barnett, J.Bibby, et al. Crystal structure of the nipah virus phosphoprotein tetramerization domain. J Virol. 2014;88:758–762. doi:10.1128/JVI.02294-13.
56. M.Ouizougun-Oubari, N.Pereira, B.Tarus, et al. A druggable pocket at the nucleocapsid/phosphoprotein interaction site of human respiratory syncytial virus. J Virol. 2015;89:11129–11143. doi:10.1128/JVI.01612-15.• identification of a candidate target site for novel PPIs blocking the interaction of RSV P and N proteins.
57. C.Leyrat, M.Renner, K.Harlos, et al. Solution and crystallographic structures of the central region of the phosphoprotein from human metapneumovirus. PLoS One. 2013;8:e80371. doi:10.1371/journal.pone.0080371.
58. M.Galloux, G.Gabiane, J.Sourimant, et al. Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein. J Virol. 2015;89:3484–3496. doi:10.1128/JVI.03666-14.
59. D.Kolakofsky, P.Le Mercier, F.Iseni, et al. Viral DNA polymerase scanning and the gymnastics of Sendai virus RNA synthesis. Virology. 2004;318:463–473.
60. M.Galloux, B.Tarus, I.Blazevic, et al. Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein. J Virol. 2012;86:8375–8387. doi:10.1128/JVI.00058-12.
61. R.L.Kingston, W.A.Baase, L.S.Gay. Characterization of nucleocapsid binding by the measles virus and mumps virus phosphoproteins. J Virol. 2004;78:8630–8640. doi:10.1128/JVI.78.16.8630-8640.2004.
62. P.L.Collins, M.G.Hill, J.Cristina, et al. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc Natl Acad Sci U S A. 1996;93:81–85.
63. R.W.Hardy, G.W.Wertz. The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol. 1998;72:520–526.
64. A.Asenjo, E.Calvo, N.Villanueva. Phosphorylation of human respiratory syncytial virus P protein at threonine 108 controls its interaction with the M2-1 protein in the viral RNA polymerase complex. J Gen Virol. 2006;87:3637–3642. doi:10.1099/vir.0.82165-0.
65. S.W.Mason, E.Aberg, C.Lawetz, et al. Interaction between human respiratory syncytial virus (RSV) M2-1 and P proteins is required for reconstitution of M2-1-dependent RSV minigenome activity. J Virol. 2003;77:10670–10676.
66. T.L.Cartee, G.W.Wertz. Respiratory syncytial virus M2-1 protein requires phosphorylation for efficient function and binds viral RNA during infection. J Virol. 2001;75:12188–12197. doi:10.1128/JVI.75.24.12188-12197.2001.
67. S.J.Tanner, A.Ariza, C.A.Richard, et al. Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation. Proc Natl Acad Sci U S A. 2014;111:1580–1585. doi:10.1073/pnas.1317262111.• structure of RSV M2-1, providing a basis for structure-based drug design campaigns.
68. M.L.Blondot, V.Dubosclard, J.Fix, et al. Structure and functional analysis of the RNA- and viral phosphoprotein-binding domain of respiratory syncytial virus M2-1 protein. PLoS Pathog. 2012;8:e1002734. doi:10.1371/journal.ppat.1002734.
69. M.Cancellieri, M.Bassetto, I.Widjaja, et al. In silico structure-based design and synthesis of novel anti-RSV compounds. Antiviral Res. 2015;122:46–50. doi:10.1016/j.antiviral.2015.08.003.
70. M.Hamaguchi, T.Yoshida, K.Nishikawa, et al. Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology. 1983;128:105–117.
71. A.K.Gupta, M.Mathur, A.K.Banerjee. Unique capping activity of the recombinant RNA polymerase (L) of vesicular stomatitis virus: association of cellular capping enzyme with the L protein. Biochem Biophys Res Commun. 2002;293:264–268. doi:10.1016/S0006-291X(02)00217-6.
72. T.Ogino, M.Kobayashi, M.Iwama, et al. Sendai virus RNA-dependent RNA polymerase L protein catalyzes cap methylation of virus-specific mRNA. J Biol Chem. 2005;280:4429–4435. doi:10.1074/jbc.M411167200.
73. O.Poch, B.M.Blumberg, L.Bougueleret, et al. Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol. 1990;71(Pt 5):1153–1162. doi:10.1099/0022-1317-71-5-1153.
74. M.Svenda, M.Berg, J.Moreno-Lopez, et al. Analysis of the large (L) protein gene of the porcine rubulavirus LPMV: identification of possible functional domains. Virus Res. 1997;48:57–70.
75. M.Dochow, S.A.Krumm, J.E.CroweJr., et al. Independent structural domains in the paramyxovirus polymerase protein. J Biol Chem. 2012. doi:10.1074/jbc.M111.325258.
76. W.P.Duprex, F.M.Collins, B.K.Rima. Modulating the function of the measles virus RNA-dependent RNA polymerase by insertion of green fluorescent protein into the open reading frame. J Virol. 2002;76:7322–7328.
77. D.D.Brown, B.K.Rima, I.V.Allen, et al. Rational attenuation of a morbillivirus by modulating the activity of the RNA-dependent RNA polymerase. J Virol. 2005;79:14330–14338. doi:10.1128/JVI.79.22.14330-14338.2005.
78. B.Liang, Z.Li, S.Jenni, et al. Structure of the L protein of vesicular stomatitis virus from electron cryomicroscopy. Cell. 2015;162:314–327. doi:10.1016/j.cell.2015.06.018.•• first high resolution reconstruction of a mononegavirales L protein.
79. B.Cevik, D.E.Holmes, E.Vrotsos, et al. The phosphoprotein (P) and L binding sites reside in the N-terminus of the L subunit of the measles virus RNA polymerase. Virology. 2004;327:297–306. doi:10.1016/j.virol.2004.07.002.
80. B.Cevik, S.Smallwood, S.A.Moyer. The L-L oligomerization domain resides at the very N-terminus of the sendai virus L RNA polymerase protein. Virology. 2003;313:525–536.
81. D.E.Holmes, S.A.Moyer. The phosphoprotein (P) binding site resides in the N terminus of the L polymerase subunit of sendai virus. J Virol. 2002;76:3078–3083.
82. S.M.Horikami, S.Smallwood, B.Bankamp, et al. An amino-proximal domain of the L protein binds to the P protein in the measles virus RNA polymerase complex. Virology. 1994;205:540–545. doi:10.1006/viro.1994.1676.
83. S.Smallwood, S.A.Moyer. The L polymerase protein of parainfluenza virus 3 forms an oligomer and can interact with the heterologous Sendai virus L, P and C proteins. Virology. 2004;318:439–450. doi:10.1016/j.virol.2003.09.045.
84. A.G.Malur, N.K.Gupta, P.De Bishnu, et al. Analysis of the mutations in the active site of the RNA-dependent RNA polymerase of human parainfluenza virus type 3 (HPIV3). Gene Expr. 2002;10:93–100.
85. T.Ogino, A.K.Banerjee. Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus. Mol Cell. 2007;25:85–97. doi:10.1016/j.molcel.2006.11.013.
86. M.Gopinath, M.S.Shaila. RNA triphosphatase and guanylyl transferase activities are associated with the RNA polymerase protein L of rinderpest virus. J Gen Virol. 2009;90:1748–1756. doi:10.1099/vir.0.010975-0.
87. F.Ferron, S.Longhi, B.Henrissat, et al. Viral RNA-polymerases – a predicted 2ʹ-O-ribose methyltransferase domain shared by all Mononegavirales. Trends Biochem Sci. 2002;27:222–224.
88. G.C.Paesen, A.Collet, C.Sallamand, et al. X-ray structure and activities of an essential Mononegavirales L-protein domain. Nat Commun. 2015;6:8749. doi:10.1038/ncomms9749.
89. M.Issur, F.Picard-Jean, M.Bisaillon. The RNA capping machinery as an anti-infective target. Wiley Interdiscip Rev RNA. 2011;2:184–192. doi:10.1002/wrna.43.
90. A.M.Murphy, V.Z.Grdzelishvili. Identification of sendai virus L protein amino acid residues affecting viral mRNA cap methylation. J Virol. 2009;83:1669–1681. doi:10.1128/JVI.01438-08.
91. S.V.Lim, M.B.Rahman, B.A.Tejo. Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus. BMC Bioinformatics. 2011;12(Suppl 13):S24. doi:10.1186/1471-2105-12-S13-S24.
92. E.De Clercq, J.Neyts. Antiviral agents acting as DNA or RNA chain terminators. Handb Exp Pharmacol. 2009;189:53–84.
93. V.Soriano, E.Vispo, C.De Mendoza, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013;14:1161–1170. doi:10.1517/14656566.2013.795543.
94. P.J.Wright, G.Crameri, B.T.Eaton. RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription. Arch Virol. 2005;150:521–532. doi:10.1007/s00705-004-0417-5.
95. S.Crotty, R.Andino. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect. 2002;4:1301–1307.
96. B.E.Gilbert, V.Knight. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 1986;30:201–205.
97. Y.Furuta, K.Takahashi, Y.Fukuda, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46:977–981.
98. Y.Furuta, B.B.Gowen, K.Takahashi, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446–454. doi:10.1016/j.antiviral.2013.09.015.
99. J.Deval, J.Hong, G.Wang, et al. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2ʹ-fluoro-4ʹ-chloromethyl-cytidine triphosphate. PLoS Pathog. 2015;11:e1004995. doi:10.1371/journal.ppat.1004995.
100. V.A.Laganas, E.F.Dunn, R.E.McLaughlin, et al. Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen. Antiviral Res. 2014;115C:71–74.
101. M.P.De Bethune. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010;85:75–90. doi:10.1016/j.antiviral.2009.09.008.
102. A.Basavapathruni, K.S.Anderson. Reverse transcription of the HIV-1 pandemic. FASEB J. 2007;21:3795–3808.
103. I.Usach, V.Melis, J.E.Peris. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013;16:1–14.
104. K.Das, A.D.ClarkJr., P.J.Lewi, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47:2550–2560. doi:10.1021/jm030558s.
105. D.S.Matharu, D.P.Flaherty, D.S.Simpson, et al. Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity. J Med Chem. 2014;57:10314–10328. doi:10.1021/jm500902x.
106. M.Liuzzi, S.W.Mason, M.Cartier, et al. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol. 2005;79:13105–13115. doi:10.1128/JVI.79.20.13105-13115.2005.
107. C.L.Tiong-Yip, L.Aschenbrenner, K.D.Johnson, et al. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother. 2014;58:3867–3873. doi:10.1128/AAC.02540-14.
108. J.J.Yoon, S.A.Krumm, J.M.Ndungu, et al. Target analysis of the experimental measles therapeutic AS-136A. Antimicrob Agents Chemother. 2009;53:3860–3870. doi:10.1128/AAC.00503-09.
109. H.Hwang, T.Vreven, J.Janin, et al. Protein-protein docking benchmark version 4.0. Proteins. 2010;78:3111–3114. doi:10.1002/prot.22830.
110. M.R.Arkin, Y.Tang, J.A.Wells. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol. 2014;21:1102–1114. doi:10.1016/j.chembiol.2014.09.001.
111. C.M.Labbe, G.Laconde, M.A.Kuenemann, et al. iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov Today. 2013;18:958–968. doi:10.1016/j.drudis.2013.05.003.
112. M.J.Basse, S.Betzi, R.Bourgeas, et al. 2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res. 2013;41:D824–827. doi:10.1093/nar/gks1002.
113. A.P.Higueruelo, A.Schreyer, G.R.Bickerton, et al. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des. 2009;74:457–467. doi:10.1111/j.1747-0285.2009.00889.x.
114. M.C.Smith, J.E.Gestwicki. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med. 2012;14:e16. doi:10.1017/erm.2012.10.
115. J.Chapman, E.Abbott, D.G.Alber, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007;51:3346–3353. doi:10.1128/AAC.00211-07.
116. S.Challa, A.D.Scott, O.Yuzhakov, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015;59:1080–1087. doi:10.1128/AAC.04119-14.
117. F.Marty 2007. A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of RSV604 in adults with respiratory syncytial virus infection following stem cell transplantation. IXth International Symposium on Respiratory Viral Infections, Causeway Bay, Hong Kong, 2007 Mar 3–6.
118. R.L.Mackman, M.Sangi, D.Sperandio, et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015;58:1630–1643. doi:10.1021/jm5017768.
119. J.P.DeVincenzo, M.W.McClure, J.A.Symons, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373:2048–2058. doi:10.1056/NEJMoa1413275.• study confirmed efficacy in human trial.
120. J.Dent, S.Grieve, R.Harland, et al. 2005. Multiple-dose safety and pharmacokinetics of A-60444, a novel compound active against respiratory syncytial virus (RSV). 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC.
121. W.J.Weiss, T.Murphy, M.E.Lynch, et al. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J Med Primatol. 2003;32:82–88.
122. K.L.Yu, N.Sin, R.L.Civiello, et al. Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett. 2007;17:895–901. doi:10.1016/j.bmcl.2006.11.063.
123. Safety Study of Oral BTA9881 to Treat RSV Infection. Biota Scientific Management Pty Ltd. U.S. National Institutes of Health. 2007. Available from: https://clinicaltrials.gov/ct2/show/NCT00504907.
124. G.Ispas, A.Koul, J.Verbeeck, et al. Antiviral activity of TMC353121, a Respiratory Syncytial Virus (RSV) fusion inhibitor, in a non-human primate model. PLoS One. 2015;10:e0126959. doi:10.1371/journal.pone.0126959.
125. A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers. MicroDose Therapeutx, Inc. U.S. National Institute of Health. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT01489306.